Breast Cancer research work at the University Hospitals of North Midlands NHS Trust has received national recognition with a prestigious award won by Clinical Oncology Consultant Professor Murray Brunt.
Professor Brunt is the winner of a National Institute for Health Research (NIHR) Industry Principal Investigator Award in recognition of his work leading on research trials at the Trust. The award recognises and celebrates the expertise of commercial principal investigators (PIs) who are responsible for NIHR supported research sites, ensuring that patients are appropriately recruited into research studies.
“The award is very exciting and it is a tribute to the tremendous team of research and clinical staff that I lead. We are focussed on clinical excellence for our patients and we see cutting-edge clinical research as an integral part of that excellence.”
Judges were impressed with the trial work being carried out by Professor Brunt and his team.
A number of successful trials at UHNM were highlighted as part of Professor Brunt’s nomination in the category for Consistently Delivering a Study to Time and Target. These included the APHINITY Trial, which has signed up more than 171% of its original recruitment target, and the BMS IMAGE Trial which has recruited 225% more patients than its original target.
“We are very proud that we are the top recruiting centre in Western Europe for the global PRESENT Trial, which is the first phase three breast cancer vaccine trial. For the KAITLIN Trial looking at a novel antibody drug for breast cancer patients, we recruited the first patient in Europe and we are also the top recruiting centre in the UK.
“Trials are a wonderful opportunity for local patients, who wish to take part, and offer the chance to gain access to cutting-edge treatments and world-class developments in medical research for Breast Cancer.”
Professor Brunt was nominated by the Trust’s Commercial Research Specialist Michelle Till in the Research and Development Team.
“My role within R&D has given me the pleasure to work with Professor Brunt through supplying the Oncology Research Team with its commercially sponsored studies. After initially meeting with Professor Brunt, I immediately recognised his passion and dedication to clinical trials and the team’s hard work, determination, and commitment to conducting these trials to deliver better patient outcomes.”
Dr Jeremy Kirk, Clinical Director of the Clinical Research Network (CRN): West Midlands, said:
“We are very proud of the contribution of the Network’s Principal Investigators to the success of the NIHR CRN Commercial Portfolio, and of the impact they have on the UK commercial clinical research landscape, driving the commercial portfolio and helping make the CRN: West Midlands a success. It’s great to see them recognised for this valuable and important work.”